These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 21469926

  • 1. Galectin-1 and immunotherapy for brain cancer.
    Verschuere T, De Vleeschouwer S, Lefranc F, Kiss R, Van Gool SW.
    Expert Rev Neurother; 2011 Apr; 11(4):533-43. PubMed ID: 21469926
    [Abstract] [Full Text] [Related]

  • 2. [Peptide vaccination therapy for malignant glioma].
    Yamanaka R, Itoh K.
    Brain Nerve; 2007 Mar; 59(3):251-61. PubMed ID: 17370651
    [Abstract] [Full Text] [Related]

  • 3. Novel immunotherapeutic approaches to glioma.
    Yamanaka R.
    Curr Opin Mol Ther; 2006 Feb; 8(1):46-51. PubMed ID: 16506525
    [Abstract] [Full Text] [Related]

  • 4. [Dendritic cell therapy for malignant glioma].
    Yamanaka R, Homma J, Yajima N, Tsuchiya N, Tanaka R.
    No To Shinkei; 2003 Sep; 55(9):771-80. PubMed ID: 14571839
    [Abstract] [Full Text] [Related]

  • 5. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
    Verschuere T, Toelen J, Maes W, Poirier F, Boon L, Tousseyn T, Mathivet T, Gerhardt H, Mathieu V, Kiss R, Lefranc F, Van Gool SW, De Vleeschouwer S.
    Int J Cancer; 2014 Feb 15; 134(4):873-84. PubMed ID: 23929302
    [Abstract] [Full Text] [Related]

  • 6. Dendritic cell vaccines.
    Yamanaka R, Kajiwara K.
    Adv Exp Med Biol; 2012 Feb 15; 746():187-200. PubMed ID: 22639169
    [Abstract] [Full Text] [Related]

  • 7. Dendritic cell-based immunotherapy for malignant gliomas.
    Akasaki Y, Black KL, Yu JS.
    Expert Rev Neurother; 2005 Jul 15; 5(4):497-508. PubMed ID: 16026233
    [Abstract] [Full Text] [Related]

  • 8. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
    Everson RG, Graner MW, Gromeier M, Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS, Friedman AH, Bigner DD, Sampson JH.
    Expert Rev Anticancer Ther; 2008 May 15; 8(5):717-32. PubMed ID: 18471045
    [Abstract] [Full Text] [Related]

  • 9. Glioma-specific antigens for immune tumor therapy.
    Skog J.
    Expert Rev Vaccines; 2006 Dec 15; 5(6):793-802. PubMed ID: 17184218
    [Abstract] [Full Text] [Related]

  • 10. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
    Newcomb EW, Demaria S, Lukyanov Y, Shao Y, Schnee T, Kawashima N, Lan L, Dewyngaert JK, Zagzag D, McBride WH, Formenti SC.
    Clin Cancer Res; 2006 Aug 01; 12(15):4730-7. PubMed ID: 16899624
    [Abstract] [Full Text] [Related]

  • 11. Cell-Based Immunotherapy of Gliomas.
    Everson RG, Antonios JP, Liau LM.
    Prog Neurol Surg; 2018 Aug 01; 32():90-100. PubMed ID: 29990977
    [Abstract] [Full Text] [Related]

  • 12. Dendritic cell immunotherapy for malignant gliomas.
    Luptrawan A, Liu G, Yu JS.
    Rev Recent Clin Trials; 2008 Jan 01; 3(1):10-21. PubMed ID: 18474011
    [Abstract] [Full Text] [Related]

  • 13. Harnessing the immune system against human glioma.
    Dhodapkar KM, Banerjee D, Steinman RM.
    Ann N Y Acad Sci; 2005 Dec 01; 1062():13-21. PubMed ID: 16461784
    [Abstract] [Full Text] [Related]

  • 14. Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?
    Van Gool S, De Vleeschouwer S.
    Expert Rev Neurother; 2012 Oct 01; 12(10):1173-6. PubMed ID: 23082731
    [No Abstract] [Full Text] [Related]

  • 15. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma.
    Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, Kubota T, Yang WK.
    J Clin Neurosci; 2011 Aug 01; 18(8):1048-54. PubMed ID: 21715171
    [Abstract] [Full Text] [Related]

  • 16. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma.
    Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M.
    Anticancer Res; 2002 Aug 01; 22(2A):613-21. PubMed ID: 12014629
    [Abstract] [Full Text] [Related]

  • 17. Dendritic-cell- and peptide-based vaccination strategies for glioma.
    Yamanaka R.
    Neurosurg Rev; 2009 Jul 01; 32(3):265-73; discussion 273. PubMed ID: 19214609
    [Abstract] [Full Text] [Related]

  • 18. Cell- and peptide-based immunotherapeutic approaches for glioma.
    Yamanaka R.
    Trends Mol Med; 2008 May 01; 14(5):228-35. PubMed ID: 18403264
    [Abstract] [Full Text] [Related]

  • 19. Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma.
    Jiang XB, Lu XL, Hu P, Liu RE.
    Vaccine; 2009 Oct 19; 27(44):6210-6. PubMed ID: 19699331
    [Abstract] [Full Text] [Related]

  • 20. In situ dendritic cell vaccination for the treatment of glioma and literature review.
    Li M, Han S, Shi X.
    Tumour Biol; 2016 Feb 19; 37(2):1797-801. PubMed ID: 26318301
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.